Table 1.
Patient characteristics
| Characteristic | All patients |
|---|---|
| Patient number, N | 27 |
| Female, n | 19 (70%) |
| Mean age at the start of the COVID-19 pandemic, years | 41.6 ± 15.7 |
| Race | |
| Caucasian, n | 23 (85%) |
| African, n | 3 (11%) |
| Asian, n | 1 (4%) |
| Maintenance anti C5 treatment any time during pandemic, n | 8 (30%) |
| SARS-CoV-2 vaccination, n | 23 (85%) |
| 1, n | 1 (4%) |
| 2, n | 5 (22%) |
| 3, n | 11 (48%) |
| 4, n | 4 (17%) |
| 5, n | 2 (9%) |
| SARS-CoV-2 infection, n | 13 (48%) |
| Wuhan strain, n | 1 (4%) |
| Alpha, n | 0 |
| Delta, n | 1 |
| Any Omicron variant, n | 12 (44%) |
| TMA episode during pandemic, any cause | 5 (19%) |
| TMA episode after SARS-CoV-2 infection | 3 (11%) |
| TMA episode after SARS-CoV-2 vaccination | 1 (4%) |
anti C5 treatment, maintenance eculizumab or ravulizumab; SARS-CoV-2, severe acute respiratory distress syndrome corona virus 2; TMA, thrombotic microangiopathy, n = number.